Who Paid My Doc
sGC activator in SSc patients
Research payments
$941,389
Through program year 2025, $941,389 in research payments was reported against sGC activator in SSc patients, across 135 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $26,057 | 21 |
| 2024 | Research | $636,831 | 67 |
| 2023 | Research | $277,342 | 45 |
| 2022 | Research | $1,159 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Andy Abril Jacksonville, FL Named on 10 payments
- Carleigh Zahn Ann Arbor, MI Named on 6 payments
- Hanna Zembrzuska Iowa City, IA Named on 6 payments
- Ashima Makol Rochester, MN Named on 4 payments
- Srihari Veeraraghavan Atlanta, GA Named on 4 payments
- Michael Pham Scottsdale, AZ Named on 4 payments
- Flavia Castelino Boston, MA Named on 4 payments
- Fabian Mendoza Ballesteros Philadelphia, PA Named on 4 payments
- Monique Hinchcliff North Haven, CT Named on 4 payments
- Guillermo Valenzuela Plantation, FL Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.